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DrOBJECTIVES The goal of this study was to evaluate the 5-year follow-up data of the IN.PACT DEEP (Randomized
IN.PACT Amphirion Drug-Coated Balloon [DCB] vs. Standard Percutaneous Transluminal Angioplasty [PTA] for the
Treatment of Below-the-Knee Critical Limb Ischemia [CLI]) trial.
BACKGROUND Initial studies from randomized controlled trials have shown comparable short-term outcomes of DCB
angioplasty versus PTA in patients with CLI with infrapopliteal disease. However, the long-term safety and effectiveness
of DCB angioplasty remain unknown in this patient population.
METHODS IN.PACT DEEP was an independently adjudicated prospective, multicenter, randomized controlled trial that
enrolled 358 subjects with CLI. Subjects were randomized 2:1 to DCB angioplasty or PTA. Assessments through 5 years
included freedom from clinically driven target lesion revascularization, amputation, and all-cause death. Additional as-
sessments were conducted to identify risk factors for death and major amputation, including paclitaxel dose tercile.
RESULTS Freedom from clinically driven target lesion revascularization through 5 years was 70.9% and 76.0%
(log-rank p ¼ 0.406), and the incidence of the safety composite endpoint was 59.8% and 57.5% (log-rank p ¼ 0.309) in
the DCB angioplasty and PTA groups, respectively. The rate of major amputation was 15.4% for DCB angioplasty
compared with 10.6% for PTA (log-rank p ¼ 0.108). Given the recent concern regarding a late mortality signal in patients
treated with paclitaxel-coated devices, additional analyses from this study showed no increase in all-cause mortality with
DCB angioplasty (39.4%) compared with PTA (44.9%) (log-rank p ¼ 0.727). Predictors of mortality included age,
Rutherford category >4, and previous revascularization but not paclitaxel by dose tercile.
CONCLUSIONS Tibial artery revascularization in patients with CLI using DCB angioplasty resulted in comparable long-
term safety and effectiveness as PTA. Paclitaxel exposure was not related to increased risk for amputation or all-cause
mortality at 5-year follow-up. (Study of IN.PACT Amphirion Drug Eluting Balloon vs. Standard PTA for the Treatment
of Below the Knee Critical Limb Ischemia [INPACT-DEEP]; NCT00941733) (J Am Coll Cardiol Intv 2020;13:431–43)
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CD-TLR = clinically driven
target lesion revascularization
CLI = critical limb ischemia
DCB = drug-coated balloon
MAE = major adverse events
PTA = percutaneous
transluminal angioplasty
TLR = target lesion
revascularization
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432C ritical limb ischemia (CLI) is associ-ated with a high risk for cardiovas-cular events and mortality and
accounts for approximately 90% of major
amputations performed worldwide (1,2).
Below-the-knee (BTK) bypass surgery with
autologous vein grafts was the preferred
treatment for CLI in the past (3); however,
the presence of various underlying comor-
bidities and anatomic conditions precludes
a significant number of patients with CLI
from surgery. In the past decade, endovascu-
lar procedures have been on the rise, withdecreasing rates of open bypass surgery (4). Standard
percutaneous transluminal angioplasty (PTA) has
been the primary endovascular therapy used in the
infrapopliteal vascular bed, although it is associated
with poor long-term patency rates (5). Several ran-
domized clinical trials have demonstrated the
superior performance of paclitaxel drug-coated
balloon (DCB) angioplasty compared with PTA for
femoropopliteal peripheral artery lesions (6–11). How-
ever, results remain varied and inconsistent in infra-
popliteal trials, ranging from superior outcomes of
DCB angioplasty in a single-center trial (12) to no
added benefit of DCB angioplasty in multicenter trials
(13,14). Furthermore, there are no long-term follow-
up data beyond 3 years (15) for any DCB in BTK
studies until now.SEE PAGE 444The IN.PACT DEEP (Randomized IN.PACT Amphi-
rion Drug-Coated Balloon [DCB] vs. Standard Percu-
taneous Transluminal Angioplasty [PTA] for the
Treatment of Below-the-Knee Critical Limb Ischemia
[CLI]) trial was conducted on the basis of the hypoth-
esis that DCBs would significantly reduce angio-
graphically assessed target lesion late lumen loss in
patients with infrapopliteal lesions of #10 cm and
reduce clinically driven target lesion revascularization
(CD-TLR) compared with PTA at 12 months. The hy-
pothesis also postulated that DCB angioplasty wouldheinert is a compensated consultant for Abbott Vascular, Biotron
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received August 29, 2019; revised manuscript received Octoberbe noninferior to PTA with reference to the primary
safety endpoint, defined as a composite of all-cause
death, major amputation, and CD-TLR through
6 months (16). Outcomes through 12 months were re-
ported previously (13). In the report, DCB angioplasty
had comparable primary efficacy with PTA. Although
primary safety was met, there was a statistically
nonsignificant but numerically higher amputation rate
in the DCB arm comparedwith PTA through 12months.
The observed absence of efficacy superiority
compared with PTA and the unfavorable amputation
signal resulted in the sponsor’s decision to voluntarily
discontinue this DCB from the market. Nonetheless,
subject follow-up was continued through 5 years as
planned. Herein, we report the 5-year outcomes of the
IN.PACT DEEP trial. The aim was to evaluate the long-
term safety and efficacy of the IN.PACT Amphirion
DCB (Medtronic, Santa Rosa, California) in comparison
with PTA, focusing on safety parameters, particularly
major amputations and mortality.METHODS
STUDY DESIGN. The IN.PACT DEEP trial was a pro-
spective, multicenter, patient-blinded, randomized
controlled trial of the IN.PACT Amphirion DCB versus
PTA for the treatment of infrapopliteal arterial dis-
ease in patients with CLI in Rutherford class 4 to 6.
Details of the trial design and inclusion and exclusion
criteria were described previously (13,16). A total of
358 patients were enrolled across 13 European sites
from September 2009 to July 2012. Patients were
randomized 2:1 to either the IN.PACT Amphirion DCB
or PTA. Subjects were followed for a total of
60 months according to the following schedule:
30 days and 3, 6, 12, 24, 36, 48, and 60 months.
Subjects had hospital visit evaluations at 30 days and
6, 12, and 24 months. At 3, 36, 48, and 60 months,
subjects had phone follow-up and assessments
including the occurrence of reintervention, wound
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433was conducted in accordance with the principles of
the Declaration of Helsinki, ISO 14155, and Good
Clinical Practices guidelines. The ethics committees
of all investigational sites approved the trial protocol,
and written informed consent was obtained from all
subjects before enrollment.
An independent data safety monitoring and clin-
ical events committee (Genae, Antwerp, Belgium)
adjudicated all major adverse events (MAE),
including death, target limb major and minor ampu-
tations through 5 years, and target lesion revascu-
larization (TLR) through 2 years. Statistical methods
were designed by the study sponsor; the raw data
were transferred to the Baim Institute for Clinical
Research, formerly HCRI (Boston, Massachusetts),
and analyzed independently.
ENDPOINTS AND DEFINITIONS. Assessments through 5
years included freedom from CD-TLR, freedom from
major amputation, and all-cause death. CD-TLR was
defined as any TLR associated with deterioration of
Rutherford category and/or an increase in the size of
pre-existing wounds and/or occurrence of new
wounds. The safety endpoint was a composite of all-
cause death, major amputation, and CD-TLR rate
assessed through 60 months. Other secondary end-
points assessed through 5 years included MAE
(a composite of death of any cause, major amputa-
tion, minor amputation), individual components of
MAE and TLR. TLR was defined as any repeat percu-
taneous intervention or bypass surgery performed on
the target limb.
STATISTICAL ANALYSIS. Baseline demographics and
clinical characteristics were summarized on a per
subject basis; lesion characteristics were summarized
on a per lesion basis. Outcome analyses were per-
formed at a subject level. Continuous variables are
described as mean  SD, and the treatment compari-
son used Student’s t-tests or Wilcoxon rank sum
tests. Dichotomous and categorical variables are
described as counts and proportions. The Fisher exact
test or chi-square test was used to test the difference
between binary variables, and the Cochran-Mantel-
Haenszel test was used for comparison of nominal
or ordinal variables. The Kaplan-Meier method was
used to evaluate time-to-event data. The difference
in the survival curves between treatment groups was
assessed using the log-rank test. Furthermore, to
determine the likelihood of reintervention in the
presence of the competing risk for death, the cumu-
lative incidence function from competing-risk meth-
odology was used (17). A nonparametric test using a
modified chi-square test statistic was used to
compare 2 cumulative incidence functions from eachtreatment (18). Three hundred sixty-five days was
used as the annual cutoff for the analysis of the safety
and clinical endpoints. The level of statistical signif-
icance was set at p < 0.05. Statistical analyses were
performed using SAS version 9.4 (SAS Institute, Cary,
North Carolina).
Pac l i taxe l dose ca lcu lat ion and terc i le surv iva l
ana lys i s . This post hoc analysis is not a pre-specified
endpoint in the original study protocol but was con-
ducted as a consequence of a recently published
meta-analysis suggesting an excess mortality risk
following paclitaxel exposure in femoropopliteal ar-
tery interventions (19). To assess the potential impact
of paclitaxel dose on mortality in this study, nominal
paclitaxel dose received by each DCB subject during
the index procedure was calculated on the basis of
nominal dose matrix provided by the manufacturer
(Medtronic). The balloon lengths and diameters
received by each patient were captured on the index
procedure records, and the nominal paclitaxel dose
per balloon was added together to define the total
dose of paclitaxel received per patient in the index
procedure. The nominal dose determined for each
balloon are assumed to have a full effect on each
patient in the dose analysis. DCB subjects were
stratified by their survival status through 5 years with
the nominal paclitaxel doses compared between
groups and presented as summary statistics (mean,
SD, median, quartiles, and range). To further evaluate
a potential correlation of increasing dose of paclitaxel
on mortality, DCB subjects were segmented into ter-
ciles on the basis of the amount of paclitaxel received
during the index procedure (lower, middle, and up-
per). Paclitaxel dose distribution in each tercile group
was calculated and presented as summary statistics.
The cumulative incidence of all-cause death was
estimated in these 3 groups using the Kaplan-Meier
method and compared among dose terciles.
Mult ivar iab le analys i s . To identify predictive fac-
tors for all-cause death and major amputation in all
patients, univariate analyses followed by a stepwise
multivariable Cox regression model with an entry
criterion of 0.2 and a stay criterion of 0.1 were used. If
a p value was <0.2 in the univariate analysis, that
covariate was included in the multivariable analysis
to go through the stepwise selection process (20).
Clinically relevant baseline variables were included
for variable selection. The terciles of total dose of
paclitaxel received per patient in the index procedure
were forced into the final multivariable model, igno-
rant of the statistical significance of the p value.
Hazard ratios with 2-sided 95% confidence intervals
were calculated.
FIGURE 1 Subject Flowchart in the IN.PACT DEEP Trial Though 60 Months
Three hundred fifty-eight subjects were randomized 2:1 into groups that received angioplasty with the IN.PACT Amphirion drug-coated
balloon (DCB) or percutaneous transluminal angioplasty (PTA). Subjects were followed for 5 years. “Withdrew” comprises subjects who could
not be included in the analysis at the subsequent time point because of consent withdrawal or withdrawal by the investigator because of major
amputation, bedridden, untraceable, or demented or mental health deterioration. Numbers reported here are based on within window visits,
defined as 12, 24, 36, 48, and 60 months  30 days.
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434RESULTS
Three hundred fifty-eight subjects were randomized
to receive treatment with DCB angioplasty (n ¼ 239)
or PTA (n ¼ 119). Subject flow through 60-month
follow-up is shown in Figure 1. Subjects were
considered withdrawn and excluded from theanalysis at the subsequent time point when there was
a consent withdrawal or withdrawal by the investi-
gator because of major amputation, bedridden,
untraceable, or demented or mental health deterio-
ration. A total of 95 subjects in the DCB group and 49
subjects in the PTA group completed 60-month
follow-up. Overall, survival status information,
TABLE 1 Baseline Clinical and Lesion Characteristics
IN.PACT DCB
(n ¼ 239)
PTA
(n ¼ 119) p Value
Subject clinical characteristics
Age, yrs 73.3  8.2 71.7  9.9 0.129
Male 76.2 (182/239) 70.6 (84/119) 0.304
BMI, kg/m2 27.4  4.9 27.1  4.9 0.620
Hypertension 89.5 (214/239) 89.1 (106/119) 1.000
Hyperlipidemia 73.2 (175/239) 67.2 (80/119) 0.265
Diabetes mellitus 75.7 (181/239) 68.9 (82/119) 0.204
History of smoking 51.9 (124/239) 49.6 (59/119) 0.737
Prior MI 21.9 (50/228) 17.9 (20/112) 0.476
Congestive heart failure (EF <40%) 9.6 (22/229) 6.2 (7/113) 0.409
Renal insufficiency (GFR <30 ml/min) 8.6 (20/233) 12.5 (14/112) 0.254
Cerebrovascular disease 34.3 (82/239) 33.6 (40/119) 1.000
Previous target limb revascularization 32.2 (77/239) 21.8 (26/119) 0.047
Previous amputation 23.4 (56/239) 17.6 (21/119) 0.222
ABI, mm Hg 0.750  0.401 0.806  0.438 0.264
TBI, mm Hg 0.319  0.201 0.464  0.423 0.178
Rutherford category 0.622
0 0.0 (0/239) 0.0 (0/119)
1 0.0 (0/239) 0.0 (0/119)
2 0.0 (0/239) 0.0 (0/119)
3 0.0 (0/239) 0.8 (1/119)
4 14.2 (34/239) 17.6 (21/119)
5 84.1 (201/239) 77.3 (92/119)
6 1.7 (4/239) 4.2 (5/119)
Baseline lesion and
procedural characteristics
Target lesion length, cm 10.2  9.1 12.9  9.46 0.002
Target lesion RVD, mm 2.5  0.69 2.4  0.56 0.304
Total occlusions 38.6 (135/350) 45.9 (83/181) 0.114
Severe calcification 13.7 (48/350) 10.5 (19/181) 0.336
Provisional stenting 3.9 (14/359) 2.6 (5/189) 0.446
Values are mean  SD or % (n/N). Numbers are % (counts/sample size), unless otherwise stated.
ABI ¼ ankle-brachial index; BMI ¼ body mass index; DCB ¼ drug-coated balloon; EF ¼ ejection fraction;
GFR ¼ glomerular filtration rate; MI ¼ myocardial infarction; PTA ¼ percutaneous transluminal angioplasty;
RVD ¼ reference vessel diameter; TBI ¼ toe brachial index.
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435including data on patients who died during follow-
up, was available for a total of 170 patients (71.1%)
in the DCB group and 94 patients (79.0%) in the PTA
group through 5 years. Full subject baseline data,
including clinical, angiographic, and wound charac-
teristics, were described in detail previously (13).
Table 1 summarizes salient baseline characteristics
relevant to the present study. Baseline characteris-
tics were similar between the 2 groups with the
exception of mean lesion length (10.2 cm with DCB
angioplasty vs. 12.9 cm with PTA; p ¼ 0.002) and
previous TLR (32.2% with DCB angioplasty vs. 21.8%
with PTA; p ¼ 0.047). Subjects in both groups had
significant comorbidities, including diabetes, renal
insufficiency, and previous coronary revasculariza-
tion, reflecting the challenging nature of patients
with CLI.
EFFICACY OUTCOMES. Kaplan-Meier estimates of
freedom from CD-TLR (70.9% vs. 76.0%; log-rank
p ¼ 0.406) (Central Illustration) and freedom from
TLR (68.6% vs. 78.4%; log-rank p ¼ 0.236) (Figure 2)
were not significantly different between DCB angio-
plasty and PTA through 60 months. Kaplan-Meier
estimates of freedom from CD-TLR in the presence
of death as the competing risk were 75.6% for DCB
angioplasty and 79.1% for PTA (p ¼ 0.505)
(Online Figure 1).
SAFETY OUTCOMES. Safety outcomes through
60 months are reported in Table 2. Cumulative inci-
dence rates of the safety endpoint, a composite of all-
cause death, major amputation, and CD-TLR, were
59.8% in the DCB group and 57.5% in the PTA group
(log-rank p ¼ 0.309) through 60 months. Cumulative
incidence rates of major amputation in the DCB and
PTA groups were 15.4% and 10.6% (log-rank
p ¼ 0.108) through 60 months. Kaplan-Meier survival
curves comparing freedom from major amputation in
the DCB and PTA arms are shown in Figure 3A. For
survival analysis, the median follow-up time for DCB
angioplasty was 1,158 days (interquartile range: 364
to 1,812 days) and for PTA was 1,543 days (inter-
quartile range: 692 to 1,822 days). There was no safety
signal regarding the all-cause mortality rate in the
DCB group. The cumulative incidence of all-cause
death was numerically lower in the DCB group
compared with the PTA group, although it was not
statistically significant (39.4% for DCB angioplasty vs.
44.9% for PTA; log-rank p ¼ 0.727) (Table 2). Figure 3B
shows Kaplan-Meier survival curves of freedom from
all-cause death in both treatment arms.
Causes of death through 60 months as adjudicated
by the clinical events committee are summarized inOnline Table 1. There were 20.9% and 17.0% (log-rank
p ¼ 0.299) cardiac-related deaths, 6.0% and 3.8%
(log-rank p ¼ 0.278) vascular-related deaths, and
16.5% and 29.8% (log-rank p ¼ 0.032) non-
cardiovascular-related deaths in the DCB and PTA
groups, respectively. Mortality rates in the DCB and
PTA arms over the course of the 60-month period
(1- to 60-month follow-up) are summarized in Online
Figure 2. The MAE composite (death of any cause,
major amputation, minor amputation) rates were
60.8% in the DCB group and 58.4% in the PTA group
(log-rank p ¼ 0.204) (Table 2).
CONTINUOUS AND TERCILE PACLITAXEL DOSE AND
SURVIVAL ANALYSIS. The impact of paclitaxel dose
on mortality is shown in Table 3. DCB subjects who
died (n ¼ 76) received a mean paclitaxel dose of
CENTRAL ILLUSTRATION Treatment Effect of the IN.PACT Amphirion DCB in Infrapopliteal
Lesions Through 60 Months
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Zeller, T. et al. J Am Coll Cardiol Intv. 2020;13(4):431–43.
Freedom from clinically-driven target lesion revascularization (CD-TLR) was not significantly different between the drug-coated balloon
(DCB) and percutaneous transluminal angioplasty (PTA) groups through 60 months. Bars represent 95% confidence intervals.
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4364,940.5  3,918.9 mg, while DCB subjects who sur-
vived (n ¼ 162) received 4,783.7  3,295.4 mg, which
was not significantly different between the groups
(p ¼ 0.950) (Table 3).
To further assess a potential correlation of
increasing paclitaxel dose to mortality, subjects who
received paclitaxel during the index procedure (DCB
group) were segmented into terciles (lower, middle,
and upper) on the basis of the amount of nominal
paclitaxel dose given at the index procedure. Cu-
mulative incidence rates of all-cause death at each
dose group were evaluated using Kaplan-Meier es-
timates (Figure 4). The mean dose in each tercile
was 1,641.3, 3,999.4, and 8,994.1 mg in increasing
order, and the PTA group was referenced as zero
paclitaxel dose. All-cause death rates were not
significantly different (log-rank p ¼ 0.916) among
subjects with different paclitaxel doses, zero (PTA
group), lower tercile, middle tercile, and upper
tercile (DCB group), demonstrating no correlation
with increasing nominal paclitaxel doses during theindex procedure and mortality in subjects through 5
years.
PREDICTORS OF MORTALITY AND MAJOR AMPUTATION.
A multivariable Cox proportional hazard regression
analysis was performed to identify potential baseline
predictors of all-cause death through 60 months
(Table 4). Age, advanced peripheral artery disease
defined as Rutherford category >4, and previous pe-
ripheral revascularization were associated with
increased risk for death within 60 months in all sub-
jects. Paclitaxel dose terciles were not selected by the
multivariate predictors selection process, suggesting
that increasing dose of paclitaxel was not a predictor
of mortality. Furthermore, it also failed to predict
mortality when paclitaxel dose was forced into the
final model to show the potential impact. Predictors
of increased risk for major amputation through 5
years included renal insufficiency and current smok-
ing (Table 5). Similarly, none of the paclitaxel dose
terciles (lower, middle, or upper) were predictors of
FIGURE 2 Treatment Effect of the IN.PACT Amphirion DCB in Infrapopliteal Lesions Through 60 Months
Freedom from target lesion revascularization (TLR) by Kaplan-Meier estimate was not significantly different between the drug-coated balloon
(DCB) and percutaneous transluminal angioplasty (PTA) groups through 60 months. Bars represent 95% confidence intervals.
TABLE 2 Safety and Effectiveness Results of All ITT Subjects Through 60 Months by
Kaplan-Meier Estimate
IN.PACT DCB
(n ¼ 239)
PTA
(n ¼ 119)
Log-Rank
p Value
Endpoints through 60 months
Safety endpoint composite through 60 months* 59.8 (128) 57.5 (61) 0.309
All-cause death 39.4 (74) 44.9 (45) 0.727
Major target limb amputation 15.4 (30) 10.6 (9) 0.108
CD-TLR† 29.1 (50) 24.0 (22) 0.406
Safety events within 60 months
MAE composite‡ 60.8 (134) 58.4 (63) 0.204
All-cause death 39.4 (74) 44.9 (45) 0.727
Major target limb amputation 15.4 (30) 10.6 (9) 0.108
Minor target limb amputation 31.1 (63) 26.0 (28) 0.390
Secondary effectiveness endpoints within 60 months
TLR§ 31.4 (55) 21.6 (22) 0.236
CD-TLR† 29.1 (50) 24.0 (22) 0.406
Values are % (n). Percentages are Kaplan-Meier estimates of cumulative incidence (number of patients with
events). An independent clinical events committee adjudicated all MAE, including death, target limb major and
minor amputations through 5 yrs, and TLR through 2 yrs. *Defined as a composite of all-cause death, major
amputation, and CD-TLR. †Defined as any TLR associated with deterioration of Rutherford category and/or an
increase in the size of pre-existing wounds and/or occurrence of new wounds. ‡Defined as a composite of all-
cause death, major amputation of target limb, or minor amputation of target limb. §Any repeat percutaneous
intervention or bypass surgery performed on the target limb.
CD-TLR ¼ clinically-driven target lesion revascularization; ITT ¼ intention-to-treat; MAE ¼ major adverse
events; TLR ¼ target lesion revascularization; other abbreviations as in Table 1.
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437major amputation of target limb in either the regular
selection or the forced model.
DISCUSSION
In this final 5-year report from the IN.PACT DEEP
randomized trial, safety and efficacy outcomes did
not differ significantly between subjects treated with
DCB angioplasty and subjects treated with PTA.
Previously, we reported a safety signal driven by a
statistically nonsignificant but numerically higher
(2.4-fold) major amputation rate with DCB angio-
plasty compared with PTA at 12 months (12). Although
the major amputation rate was still slightly higher
(1.45-fold) with DCB angioplasty compared with PTA
through 5 years, the difference was not significant. In
light of the recently published meta-analysis sug-
gesting increased all-cause mortality following drug-
eluting technology in femoropopliteal artery disease
(19), the findings of this study found no increase in
mortality in the DCB group compared with PTA.
Furthermore, the results clearly demonstrated that
paclitaxel treatment did not correlate with either
mortality or major amputation in CLI patients.
FIGURE 3 Freedom From Major Amputation and All-Cause Death Through 60 Months
Freedom from major amputation of target limb (A) and freedom from all-cause death (B) by Kaplan-Meier estimate were not significantly
different between the drug-coated balloon (DCB) and percutaneous transluminal angioplasty (PTA) groups through 60 months. Bars
represent 95% confidence intervals.
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438The continuous innovation of endovascular tech-
nologies has generated a variety of different modal-
ities and devices, including drug-eluting stents and
DCBs for the treatment of lower extremity peripheralartery disease (21,22). Randomized trials have pro-
vided both short-term and long-term clinical evi-
dence for the use of DCBs in femoropopliteal lesions
(7,10,11,23–25). Indeed, DCBs have become the
TABLE 3 Nominal Paclitaxel Dose in All Drug-Coated Balloon Subjects
Death
(n ¼ 76)
Survival
(n ¼ 163) p Value
n 76* 162†
Mean  SD 4,940.53  3,918.86 4,783.67  3,295.44 0.950
Median (IQR) 3,829.12 (1,952.61–6,581.89) 3,851.67 (1,975.16–6,951.84)
Minimum, maximum 768.09, 22,556.69 768.09, 14,829.57
Nominal doses of paclitaxel (micrograms) are reported in all subjects in the drug-coated balloon group who died
versus survived. The nominal paclitaxel dose per balloon was calculated on the basis of nominal dose matrix
provided by the manufacturer (Medtronic). The balloon lengths and diameters received by each patient were
captured in procedure records, and the nominal paclitaxel dose per balloon was added together to define the
total dose of paclitaxel received per patient in each index procedure. *All subjects who died during the full
follow-up period, including 2 deaths after 1,825 days. †One subject in the survival group did not have sufficient
information to calculate paclitaxel dose, so paclitaxel dose was calculated on the basis of 162 subjects only.
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439treatment of choice for the revascularization of TASC
IIA and IIB femoropopliteal lesions and recom-
mended as the intended definitive therapy in this
vascular bed (26,27). In contrast, studies reporting the
use of DCBs in patients with CLI with infrapopliteal
lesions are limited to short-term outcomes (28–31),
and only a minority of them are from randomized
trials (12–14). Results across these studies varied, and
there is no consensus on the use of DCBs for the
treatment of patients with CLI with infrapopliteal
lesions. To date, the present work is the only trial
reporting 5-year follow-up data evaluating the safety
and effectiveness of DCB angioplasty in comparison
with PTA in patients with CLI with infrapopliteal le-
sions. Because there are no benchmark 5-year follow
data on DCBs, we compared the outcomes of this
study with other endovascular modalities and bypass
surgery outcomes of BTK studies available. The 5-
year repeat revascularization rate was reported in
the range of 21% to 50% (32,33) for PTA in published
research, compared with TLR rates of 21.6% for PTA
and 31.4% for DCB angioplasty in the IN.PACT DEEP
trial.
At 5-year follow-up there is no correlation between
major amputation rate and paclitaxel exposure. In
fact, the rates observed in both the DCB and PTA arms
of the IN.PACT DEEP trial are lower than those in
other contemporary studies. In the PADI trial, the
5-year major amputation rate was 19.3% in the drug-
eluting stent arm and 34% in the PTA bare-metal
stent control arm (34) compared with the 5-year ma-
jor amputation rates of 15.4% for DCB and 10.6% for
PTA in the IN.PACT DEEP trial. Conversely, reported
5-year limb salvage or freedom from amputation rates
for endovascular and bypass studies range from 75%
to 87% (33,35–38) compared with a 5-year rate of
freedom from major amputation of 84.6% for DCB
angioplasty and 89.4% for PTA in the IN.PACT DEEP
trial; both fall in the upper range. Although long-term
data are not available, not a single BTK trial
comparing DCB angioplasty with PTA has shown a
reduction of amputation rates in the DCB arm
compared with PTA (12–14). This may potentially be
due to a more complex nature of lesions in this pa-
tient population, such as the presence of higher cal-
cium burden, which may act as a barrier to drug
uptake in the arterial wall and decreases the
antiproliferative effect of paclitaxel. Indeed, studies
in femoropopliteal lesions have demonstrated
unfavorable short- and long-term outcomes of DCB
angioplasty in lesions with higher degrees of
circumferential calcium (39,40).
In a recent meta-analysis, Katsanos et al. (19) sug-
gested that there was an increased risk for mortalityat 2 and 5 years after the use of paclitaxel-coated
devices in the femoropopliteal artery. The meta-
analysis focused on studies involving femo-
ropopliteal arterial segment with predominantly
claudicant patients; nonetheless, it has become a
public concern to address the safety of paclitaxel-
eluting technologies in all peripheral artery disease
treatments, including patients with CLI with infra-
popliteal lesions. There is still no clear guideline from
regulatory bodies, although a recent update letter
from the U.S. Food and Drug Administration provided
some recommendations for paclitaxel-coated devices
(41). To shed more light on this topic, we used
exhaustive methods to evaluate whether there is any
mortality signal in the DCB arm in this study. First, 5-
year cumulative incidence of all-cause death was
compared between the DCB and PTA arms (39.4% vs.
44.9%; log-rank p ¼ 0.727), revealing no statistically
significant difference, although it was numerically
lower in the DCB group. Causes of death were similar
between the 2 arms, and there was no specific
pattern. These results are in line with those of
Secemsky et al. (42), who also reported a trend toward
a lower cumulative incidence rate of all-cause mor-
tality in patients with CLI treated with DCB compared
with PTA.
Second, continuous and tercile paclitaxel dose
analyses strongly suggested a lack of correlation be-
tween paclitaxel dose and mortality. The mean
paclitaxel dose of w5 mg received by DCB subjects in
this study is about one-half the amount reported by
Schneider at al. (43), although the same dose esti-
mation method was used in both studies. The
IN.PACT Amphion DCB, used in the present study,
has a drug dose density of 3.0 mg/mm2, whereas the
IN.PACT Admiral DCB (used for femoropopliteal and
reported by Schneider et al.) has a drug dose density
of 3.5 mg/mm2. Moreover, BTK lesions and the balloon
diameters used are smaller, resulting in a lower mean
FIGURE 4 Kaplan-Meier Estimates of Cumulative Incidence of All-Cause Death Through 60 Months by Paclitaxel Dose in All Subjects
Sixty-month all-cause death rates were not significantly different among zero (percutaneous transluminal angioplasty [PTA] group), lower,
middle, and upper paclitaxel dose terciles (drug-coated balloon [DCB] group) (log-rank p ¼ 0.905). Bars represent 95% confidence intervals.
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440paclitaxel dose in the IN.PACT DEEP trial. Despite the
drug dose difference, both studies show similar out-
comes regarding mortality, which is consistent with a
lack of dose-mortality relationship reported by
Holden et al. (44).
Finally, the multivariable model to identify pre-
dictors of all-cause death did not select any of the
paclitaxel terciles as predictors, while traditional risk
factors such as older age, Rutherford category >4, and
previous peripheral revascularization were identified
as predictors. Even when paclitaxel terciles were
forced into the final model (skipping the selection
criteria), it failed to predict mortality further,
demonstrating that there is no correlation between
paclitaxel dose and mortality in these subjects.Overall, these findings are in agreement with a series
of patient-level meta-analyses (43–47) conducted
following the report of Katsanos et al. (19). These
recent meta-analysis publications reported either no
increase in late mortality or no correlation of pacli-
taxel with mortality in subjects treated with drug-
coated devices (43–47). Furthermore, an extensive
search of the published research revealed that 5-year
mortality rates of the DCB (39.4%) and PTA (44.9%)
arms in this study were well within or lower than the
5-year mortality rates of patients with CLI undergoing
endovascular or bypass revascularization, which
ranged from 42% to 63% (33–37). Taken together,
these results strongly suggest a lack of paclitaxel ef-
fect on mortality for patients with CLI. However, the
TABLE 4 Multivariable Analysis of All-Cause Death in All ITT Subjects Through
60 Months
Predictors of All-Cause Death
Through 1,825 Days Coefficient SE Hazard Ratio (95% CI) p Value
Age 0.04 0.012 1.04 (1.02–1.07) <0.001
Rutherford category (>4 vs. #4) 0.99 0.314 2.70 (1.45–5.00) 0.002
Previous peripheral revascularization
(yes vs. no)
0.43 0.192 1.53 (1.05–2.23) 0.027
Renal insufficiency (baseline serum
creatinine $1.5 ng/dl) (yes vs. no)
0.53 0.276 1.69 (0.99–2.90) 0.057
Previous coronary revascularization
(yes vs. no)
0.36 0.199 1.44 (0.98–2.13) 0.067
Hypertension (yes vs. no) 0.50 0.276 0.61 (0.35–1.04) 0.070
Forced into the multivariable model
Paclitaxel dose (lower vs. 0)* 0.32 0.261 0.72 (0.43–1.21) 0.216
Paclitaxel dose (middle vs. 0)* 0.10 0.247 0.90 (0.56–1.46) 0.673
Paclitaxel dose (upper vs. 0)* 0.19 0.264 0.82 (0.49–1.38) 0.462
Predictors of death through 5 yrs in all patients are reported. Univariate analyses (Online Table 2) followed by a
stepwise multiple Cox regression model with an entry criterion of 0.2 and a stay criterion of 0.1 were used. If a p
value was <0.2 in the univariate analysis, that covariate was included in the multivariable analysis to go through
the stepwise selection process. Clinically relevant baseline variables were included for variable selection. *The
terciles of total dose of paclitaxel received per subject in the index procedure were not selected by the stepwise
selection method and were forced into the final multivariable model.
CI ¼ confidence interval; ITT ¼ intention-to-treat.
TABLE 5 Multivariable Analysis of Major Amputation of Target Limb in All ITT Subjects
Through 60 Months
Predictors of Major Amputation
Through 1,825 Days Coefficient SE Hazard Ratio (95% CI) p Value
Renal insufficiency (baseline serum
creatinine $1.5 ng/dl)
(yes vs. no)
1.01 0.438 2.75 (1.17–6.50) 0.021
Smoking (current vs. never) 0.98 0.445 2.66 (1.11–6.36) 0.028
Smoking (previous vs. never) 0.27 0.395 1.308 (0.60–2.84) 0.498
Male (male vs. female) 1.02 0.556 2.79 (0.94–8.29) 0.066
Rutherford category (>4 vs. #4) 1.33 0.730 3.80 (0.91–15.90) 0.068
Forced into the multivariable model
Paclitaxel dose (lower vs. 0)* 0.56 0.462 1.74 (0.70–4.31) 0.230
Paclitaxel dose (middle vs. 0)* 0.80 0.435 2.23 (0.95–5.23) 0.065
Paclitaxel dose (upper vs. 0)* 0.006 0.531 0.99 (0.35–2.82) 0.990
Predictors of major amputation of target limb through 5 yrs in all patients are reported. Univariate analyses
(Online Table 3) followed by a stepwise multiple Cox regression model with an entry criterion of 0.2 and a stay
criterion of 0.1 were used. If a p value was <0.2 in the univariate analysis, that covariate was included in the
multivariable analysis to go through the stepwise selection process. Clinically relevant baseline variables were
included for variable selection. Smoking status was self-reported. *The terciles of total dose of paclitaxel
received per subject in the index procedure were not selected by the stepwise selection method and were forced
into the final multivariable model.
CI ¼ confidence interval; ITT ¼ intention-to-treat.
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441IN.PACT DEEP trial was not designed to evaluate
long-term mortality or drug dose analysis, and these
findings are not confirmatory of either way. Further
studies in this topic with a real-world, large patient
cohort would provide more clarity on this topic.
There are lessons to be learned from the findings of
the IN.PACT DEEP trial. The absence of superior
effectiveness outcomes of DCB angioplasty in the
IN.PACT DEEP trial further emphasizes that although
revascularization is the first-line treatment for pa-
tients with CLI, several other factors could influence
the results of a clinical trial, such as wound care,
podiatry surveillance, and secondary cardiovascular
risk management. The protocol should include
appropriate guidelines to monitor these various fac-
tors that may have a role in the outcome. In addition,
the inadequacy of the IN.PACT Amphirion DCB itself
was postulated. The IN.PACT Amphirion DCB has a
paclitaxel-excipient (urea) coating that was applied
while the balloon bladder remained in a closed
(wrapped) configuration, which leaves approximately
two-thirds of the balloon surface uncoated. Addi-
tionally, the coating process involved the manual
application of the coating, resulting in variations in
coating uniformity. The majority of the adherent
paclitaxel was thus exposed during delivery and
potentially lost during transit to the vessel lesion.
There was also a marked difference in the balloon
material between the IN.PACT Amphirion DCB and
the IN.PACT Admiral DCB (for femoropopliteal indi-
cation), possibly resulting in a significant difference
in their outcomes. Despite the failure of the trial, the
low TLR, major amputation, and mortality rates
observed in the IN.PACT DEEP trial compared with
previous infrapopliteal studies are highly encour-
aging for future DCB trials.
There are several ongoing BTK trials for paclitaxel-
coated balloons. Six-month outcomes from the
Lutonix BTK trial were published (48), and AcoArt II
and Ranger BTK single-center study were presented
at the Leipzig Interventional Course (49,50). The
IN.PACT BTK randomized study, a completely
different trial from IN.PACT DEEP, reported enroll-
ment completion; this study compares the IN.PACT
014 DCB (different from the IN.PACT Amphirion DCB)
with PTA. The ILLUMENATE BTK study will assess
the safety and effectiveness of the Stellarex DCB
versus PTA. In addition to paclitaxel-coated balloons,
there are limus-eluting devices available worldwide
for BTK treatment (51).
STUDY LIMITATIONS. This was a single-blinded (pa-
tient-blinded) trial; operators could not be blinded to
the assigned treatment. The trial design had otherlimitations as well. Although IN.PACT DEEP was a
large study, the population size was not powered to
assess major amputation or mortality as long-term
endpoints. Clinical follow-up was not mandatory
beyond 24 months according to the study protocol.
Despite limiting long-term follow-up to phone con-
tact, a significant rate of loss to follow-up was
observed in both treatment groups. An accepted and
standardized definition of planned major amputation
PERSPECTIVES
WHAT IS KNOWN? Lower extremity revasculariza-
tion is the first-line treatment choice in patients with
CLI, with the goal of relieving rest pain, improving
wound healing, and preventing major limb amputa-
tion. So far, short-term outcomes following DCB an-
gioplasty of infrapopliteal arteries are conflicting with
regard to technical efficacy and clinical outcomes, and
long-term data are not yet available.
WHAT IS NEW? The long-term follow-up data
suggest that angioplasty with the IN.PACT Amphirion
DCB and PTA are feasible for the treatment of patients
with CLI with infrapopliteal lesions. Within the limi-
tations of trial design, no difference in clinical per-
formance was found in patients with CLI treated with
the IN.PACT Amphirion DCB or PTA, including major
amputation and mortality.
WHAT IS NEXT? In future DCB BTK trials, careful
consideration should be given to balloon materials,
coatings, drug concentrations, and the inclusion of
specific guidelines for wound care, podiatry
surveillance, management of comorbidities, and
vessel preparation methods to clarify and
improve outcomes.
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442was not implemented in the trial. The study protocol
did not guide or provide standards for wound sur-
veillance and care, and wound management was
administered according to the individual sites’ stan-
dards of care.
CONCLUSIONS
The results of the IN.PACT DEEP randomized
controlled trial showed comparable effectiveness and
safety outcomes for the DCB and PTA arms. The
paclitaxel-coated IN.PACT Amphirion DCB was not
efficient in terms of reducing restenosis and TLR rates
compared with PTA. However, in the long term, no
statistically significantly increased amputation or all-
cause mortality rates were found. Further studies
using more effective drug coatings in this challenging
patient population are warranted.
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